Form 8-K - Current report:
SEC Accession No. 0001104659-23-031350
Filing Date
2023-03-13
Accepted
2023-03-10 18:53:27
Documents
13
Period of Report
2023-03-10
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm239238d1_8k.htm   iXBRL 8-K 27824
  Complete submission text file 0001104659-23-031350.txt   246811

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cycc-20230310.xsd EX-101.SCH 3271
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cycc-20230310_def.xml EX-101.DEF 27200
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cycc-20230310_lab.xml EX-101.LAB 36811
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cycc-20230310_pre.xml EX-101.PRE 25822
7 EXTRACTED XBRL INSTANCE DOCUMENT tm239238d1_8k_htm.xml XML 5205
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50626 | Film No.: 23725222
SIC: 2834 Pharmaceutical Preparations